Humira Biosimilar Market 2026 Market Size And Growth Forecast: Key Trends To Watch

Humira Biosimilar Market Report

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Humira Biosimilar Market Value Growth And Long-Term Outlook

The humira biosimilar market has experienced substantial expansion in recent years. It is projected to grow from $3.67 billion in 2025 to $4.12 billion in 2026, at a compound annual growth rate (CAGR) of 12.3%. The historical increase can be attributed to several factors, including the patent expiry of humira, the elevated treatment costs associated with branded biologics, a rising prevalence of autoimmune diseases, supportive regulatory frameworks for biosimilar approvals, and the imperative from payers to curtail expenditures on biologic drugs.

The Humira biosimilar market is anticipated to experience significant expansion over the next few years. It is projected to achieve a market size of $6.53 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.2%. This growth throughout the forecast period can be attributed to several factors, including the increased integration of biosimilars into clinical practice, expanded reimbursement options for biosimilar treatments, a rise in physician confidence regarding the efficacy of biosimilars, an increase in approvals for interchangeable biosimilars, and growing patient access initiatives for more affordable biologic medications. Prominent trends expected during this period include the broadening adoption of adalimumab biosimilars across various autoimmune indications, a stronger emphasis on cost management in biologic therapies, greater acceptance of interchangeable biosimilars by healthcare providers, an increasing demand for high-concentration and citrate-free formulations, and heightened competition among biosimilar manufacturers.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=92080924&type=smp&name=Humira%20Biosimilar%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Humira Biosimilar Market Industry Drivers: What’s Behind The Revenue Growth?

The growing occurrence of autoimmune conditions is anticipated to drive the expansion of the humira biosimilar market in the future. These conditions arise when the immune system erroneously identifies and assails the body’s healthy cells, tissues, or organs. An increasing incidence of autoimmune diseases is connected to environmental contaminants, which compromise immune function and raise the likelihood of autoimmune responses. Humira biosimilars function by inhibiting tumor necrosis factor (TNF), a protein responsible for inflammation in these diseases. This action aids in dampening the immune response, thereby easing symptoms and safeguarding healthy tissues from harm. As an illustration, in August 2024, data from Public Health Scotland, a national organization based in Scotland, indicated that the Scottish Multiple Sclerosis Register (SMSR) documented 455 new MS patient diagnoses in 2023. Consequently, the rising occurrence of autoimmune conditions is fueling the expansion of the humira biosimilar market.

Humira Biosimilar Market Segment Outlook: Which Categories Are Growing Fastest?

The humira biosimilar market covered in this report is segmented –

1) By Product Type: Adalimumab Biosimilars, High-Concentration Adalimumab Biosimilars, Citrate-Free Adalimumab Biosimilars

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

3) By Application: Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Ulcerative Colitis, Ankylosing Spondylitis, Other Applications

Subsegments:

1) By Adalimumab Biosimilars: Citrate-Containing, Standard-Concentration Formulations, Citrate-Free, Standard-Concentration Formulations

2) By High-Concentration Adalimumab Biosimilars: Citrate-Containing High-Concentration Formulations, Citrate-Free High-Concentration Formulations

3) By Citrate-Free Adalimumab Biosimilars: Standard-Concentration Citrate-Free Formulations, High-Concentration Citrate-Free Formulations

#Humira Biosimilar Market Growth Trends: What’s Shaping The Future Outlook?

Leading companies in the humira biosimilar market are concentrating on developing advanced products, such as tumor necrosis factor (TNF) blockers, with the goal of delivering more cost-effective choices for autoimmune disease management. Tumor necrosis factor (TNF) blockers are biologic medications that inhibit the action of TNF, a principal protein involved in inflammation. An example is that in July 2023, Organon & Co., a US-based pharmaceutical company, collaborated with Samsung Bioepis Co., Ltd., a South Korea-based biotech company, for the introduction of HADLIMA, a biosimilar to Humira. HADLIMA is provided in both citrate-free high-concentration (100 mg/mL) and citrate-containing low-concentration (50 mg/mL) presentations, mirroring the choices offered by the originator Humira, and is designed to enhance patient availability and reduce costs. The product is provided at a substantial price reduction, about 85% lower than Humira’s list price, and further complemented by patient assistance initiatives. This introduction occurs after a global settlement permitting U.S. supply and represents a significant achievement in broadening therapeutic choices for chronic autoimmune diseases in the U.S.

Humira Biosimilar Market Leading Companies And Competitive Benchmarking

Major companies operating in the humira biosimilar market are Amgen Inc., Pfizer Inc., Samsung Biologics, Biocon Limited, Celltrion Inc., Boehringer Ingelheim GmbH, Sandoz Group AG, Fresenius Kabi AG, Alvotech, Coherus BioSciences Inc., Zydus Lifesciences Ltd., Hetero Drugs Ltd., LG Chem Ltd., Torrent Pharmaceuticals Ltd., Fujifilm Holdings Corporation, Teva Pharmaceutical Industries Ltd., Merck KGaA, Organon & Co., Cipla Limited, Dr. Reddy’s Laboratories Ltd.

View The Full Humira Biosimilar Market Report:

https://thebusinessresearchcompany.com/report/humira-biosimilar-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Humira Biosimilar Market Regional Analysis: Which Geography Leads On Revenue?

North America was the largest region in the humira biosimilar market in 2025. The regions covered in the humira biosimilar market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model